TECH - Bio-Techne Corp logo

TECH

Bio-Techne Corp

Bio-Techne Corporation develops and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing, focusing on proteins, diagnostic assays, and genomics for academic, clinical, and pharmaceutical markets globally.

βš•οΈ Healthcare NASDAQ Listed 1989 $ USD
$1,000 invested 30 years ago β†’$62,541today

Score Overview

1 Year
Score
Net Growth147.77%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth-0.38%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score6.1
Net Growth29.52%
Net Trend60%
Net Income Consistencyβ€”
Rev Growth30.50%
Rev Trend80%
Revenue Consistencyβ€”
10 Years
Score
Net Growth74.07%
Net Trend50%
Net Income Consistency
Rev Growth143.48%
Rev Trend90%
Revenue Consistency
20 Years
Score5.9
Net Growth147.93%
Net Trend60%
Net Income Consistency
Rev Growth499.67%
Rev Trend90%
Revenue Consistency
30 Years
Score
Net Growth21x
Net Trend70%
Net Income Consistency
Rev Growth22x
Rev Trend93%
Revenue Consistency
All Time
Score
Net Growth454x
Net Trend76%
Net Income Consistency
Rev Growth97x
Rev Trend95%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Bio-Techne Corp has ranked, year by year

Measure
Fundamentals Window

Showing 30 years ranking history by HDB Score.

Top 50 on HDB Score for 2 consecutive years, since 2020, through 2021.

  • TECH

2020: 5.0% Β· 2021: 3.6% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 72.51β€”
1 Year2025-09-26
$ 51.5040.79%
5 Years2021-09-28
$ 118.87-39.00%
10 Years2016-09-28
$ 25.49184.44%
20 Years2006-09-28
$ 10.606x
30 Years1996-09-27
$ 1.1662x
All Time1989-02-09
$ 0.09799x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 1.21B$ 181M$ 264M
2025$ 1.21B$ 73M$ 162M
2024$ 1.15B$ 168M$ 152M
2023$ 1.13B$ 285M$ 204M
2022$ 1.10B$ 272M$ 247M
2021$ 931M$ 140M$ 231M
2020$ 738M$ 229M$ 270M
2019$ 714M$ 96M$ 166M
2018$ 642M$ 125M$ 181M
2017$ 563M$ 77M$ 157M
2016$ 499M$ 104M$ 95M
2015$ 452M$ 107M$ 110M
2014$ 357M$ 110M$ 363M
2013$ 310M$ 112M$ 332M
2012$ 314M$ 112M$ 268M
2011$ 289M$ 112M$ 140M
2010$ 269M$ 109M$ 138M
2009$ 263M$ 105M$ 202M
2008$ 257M$ 103M$ 206M
2007$ 223M$ 85M$ 164M
2006$ 202M$ 73M$ 108M
2005$ 178M$ 66M$ 97M
2004$ 161M$ 52M$ 176M
2003$ 145M$ 45M$ 117M
2002$ 130M$ 27M$ 97M
2001$ 115M$ 34M$ 97M
2000$ 103M$ 26M$ 59M
1999$ 90M$ 16M$ 29M
1998$ 67M$ 15M$ 27M
1997$ 60M$ 10M$ 8M
1996$ 54M$ 8M$ 7M
1995$ 47M$ 6M$ 5M
1994$ 40M$ 5M$ 5M
1993$ 28M$ 4M$ 4M
1992$ 22M$ 2M$ 4M
1991$ 19M$ 1M$ 2M
1990$ 15M$ 1M$ 1M
IPO1989$ 12M$ 400K$ 1M
TECH - Bio-Techne Corp logo

Bio-Techne Corp fundamental performance

Between 2021 and 2026, revenue grew from $ 931M to $ 1.21B and net income grew from $ 140M to $ 181M. Revenue increased in 4 of those 5 years; net income in 3.

Across Bio-Techne Corp's full reported history, from 1989 to 2026, revenue grew from $ 12M to $ 1.21B and net income grew from $ 400K to $ 181M. Revenue increased in 95% of the years measured; net income in 76%.

Bio-Techne Corp currently holds a 20-year HDB Score of 5.9 out of 10. How the HDB Score is calculated.

Membership

Continue TECH’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies